Month: November 2012

No Image

OneMedPlace Announces Program Updates for Its 6th Annual “OneMedForum,” Jan. 7-9, 2013, in San Francisco

November 29, 2012 OneMedPlace Team 0

The 6th Annual OneMedForum will take place concurrently with the JP Morgan Healthcare Conference and will feature over 1,000 attendees and more than 100 emerging growth companies from the biotech and medical device sectors. The conference draws a diverse investor attendee base, including: venture capital, private equity, angel networks, family offices, hedge funds, high-net-worth individuals, international investors, research analysts, and strategic partners.

No Image

Release: Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinson’s Disease

November 28, 2012 OneMedPlace Team 0

Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.

No Image

Diagnostics: Biomarkers, Gene Patents, and Personalized Medicine in Jeopardy

November 19, 2012 OneMedPlace Team 1

Fallout from the the US Supreme Court landmark decision to deny two patents to Prometheus Laboratories may complicate the future profitability of the industry. If this is indeed a precedent-setting decision, biomarker patents may now fall under the realm of “law of nature”, cutting off the prospect of exclusive market penetration that once justified the significant research and development onus in the early stages.

No Image

OneMedRadio: DARA BioSciences CEO on Oncology Market Opportunity, Key Catalysts

November 9, 2012 OneMedPlace Team 0

In Part II of our discussion with DARA Biosciences (NASDAQ: DARA) CEO and Chief Medical Officer Dr. David Drutz, we look into key catalysts for the specialty pharmaceutical company. Dr. Drutz discusses the medical need for the oral-liquid tamoxifen, Soltamox, licensed to DARA by UK-based Rosemont Pharmaceuticals — as well as the market opportunity in developing oncology services.